A Phase 2, Randomized, Open Label, Multiple-Dose, Comparator, Parallel-Group, Safety and Tolerance Study of Buprenorphine Sublingual Spray (0.5 mg TID) Versus Standard of Care Post-Operative Narcotic Therapy for the Treatment of Post-Operative Pain

Trial Profile

A Phase 2, Randomized, Open Label, Multiple-Dose, Comparator, Parallel-Group, Safety and Tolerance Study of Buprenorphine Sublingual Spray (0.5 mg TID) Versus Standard of Care Post-Operative Narcotic Therapy for the Treatment of Post-Operative Pain

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Feb 2018

At a glance

  • Drugs Buprenorphine (Primary) ; Morphine; Oxycodone
  • Indications Postoperative pain
  • Focus Adverse reactions
  • Sponsors INSYS Therapeutics, Inc
  • Most Recent Events

    • 02 Jan 2018 Planned End Date changed from 28 Dec 2017 to 28 Jan 2018.
    • 02 Jan 2018 Planned primary completion date changed from 28 Dec 2017 to 28 Jan 2018.
    • 06 Dec 2017 Status changed from active, no longer recruiting to completed, according to an INSYS Therapeutics, Inc media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top